Levomefolic acid

Folate Analog

Key facts

Levomefolic acid is an ofp drug in the Folate Analog class catalogued in DrugCentral. It was first approved by the FDA in 2010. DrugCentral lists 1 molecular target, including TYMS. Recorded indications include Acne vulgaris, Contraception and Premenstrual dysphoric disorder.

• Approval status: ofp (first approved 2010 by the FDA).
• Drug class: Folate Analog.
• Molecular targets: TYMS (1 listed in DrugCentral).
• Indications: Acne vulgaris, Contraception and Premenstrual dysphoric disorder.
• Molecular formula: C20H25N7O6; molecular weight 459.46 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (3)

• Acne vulgaris
• Contraception
• Premenstrual dysphoric disorder

Off-label uses (1)

• Polycystic ovaries

Contraindications (57)

• Acute nephropathy
• Adrenal cortical hypofunction
• Asthma
• Bed-ridden
• Body fluid retention
• Breast lump
• Carcinoma of female breast
• Cardiovascular event risk
• Cerebrovascular accident
• Chloasma
• Chorea
• Chronic heart failure
• Deep venous thrombosis
• Dementia
• Depressive disorder
• Diabetes mellitus
• Diplopia
• Disease of liver
• Disorder of coronary artery
• Disorder of gallbladder
• Endometrial carcinoma
• Endometriosis
• Epilepsy
• Estrogen receptor positive tumor
• Family history of malignant neoplasm of breast
• Functional visual loss
• Hepatic porphyria
• Humoral hypercalcemia of malignancy
• Hypercholesterolemia
• Hyperkalemia
• + 27 more

Mechanism & targets

• Established pharmacologic class: Folate Analog

Molecular targets (1)

Target	Gene	Action	Activity
Thymidylate synthase	TYMS	unknown	—

Regulatory approvals (1)

Date	Agency	Marketed as	Applicant	Orphan
2010-09-24	FDA	—	BAYER HLTHCARE

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Off label use	229.8
Product use in unapproved indication	191.8
Synovitis	172.2
Product dose omission issue	171.7
Contraindicated product administered	161.8
Diarrhoea	159.1
Treatment failure	143.4
Fatigue	133.7
Fall	132.5
Systemic lupus erythematosus	129.8
Glossodynia	125.8
Infusion related reaction	123.5

Chemical structure

Full physicochemical, ADMET and 3D-structure analysis of Levomefolic acid is on its molecule page.

• Molecular formula: C₂₀H₂₅N₇O₆
• Molecular weight: 459.46 g/mol
• CAS number: 31690-09-2
• InChIKey: ZNOVTXRBGFNYRX-STQMWFEESA-N
• PubChem CID: 135398561

CN1[C@@H](CNC2=CC=C(C=C2)C(=O)N[C@@H](CCC(O)=O)C(O)=O)CNC2=C1C(=O)N=C(N)N2

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Levomefolic acid used for?

DrugCentral lists the following indications for Levomefolic acid: Acne vulgaris, Contraception and Premenstrual dysphoric disorder.

How does Levomefolic acid work?

Its molecular targets in DrugCentral include TYMS.

When was Levomefolic acid first approved?

Levomefolic acid was first approved by the FDA in 2010.

What drug class does Levomefolic acid belong to?

Levomefolic acid is in the Folate Analog class.

What is the chemical formula of Levomefolic acid?

Levomefolic acid has the molecular formula C20H25N7O6 and a molecular weight of 459.46 g/mol.

Sources

• DrugCentral drug card 4621 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL1231574 — compound record and bioactivity
• PubChem CID 135398561 — chemical identifiers
• DrugBank DB11256 — drug record
• FDA UNII 8S95DH25XC — substance identity
• DailyMed: FDA labels for Levomefolic acid — current prescribing information (label search)
• UniProt P04818 (TYMS) — target protein
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral

How this page is built: methodology · editorial policy & corrections.